The effect of blue-blocking and neutral intraocular lenses on circadian photoentrainment and sleep one year after cataract surgery
Brøndsted et al.
The finding, in our words
One year after cataract surgery, blue-blocking intraocular lenses improved sleep efficiency by two percentage points but suppressed nocturnal melatonin by 50% relative to neutral lenses, with actigraphy providing objective sleep measures alongside 24-hour melatonin profiles. This demonstrates the value of digital biomarkers in tracking outcomes remotely.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Adjuvant chemotherapy reduced sleep efficiency by up to ten percentage points and disrupted sleep-wake rhythm in breast cancer patients, while first-morning urinary melatonin metabolite levels fell by up to fifteen percent. The study shows that wrist actigraphy and home urine collection can remotely track these treatment effects, validating decentralised monitoring in oncology.
In progressive multiple sclerosis, higher serum neurofilament light chain levels were associated with reduced daily step counts from wearables, while higher step counts were linked to lower sNfL. A ten percent increase in steps corresponded to a 0.015 decrease in sNfL z-score, suggesting rising sNfL may predict subsequent mobility decline.
Joseph et al., Annals of clinical and translational neurology (paywalled) · source ↗
Wearable biochemical monitoring requires a complete measurement chain that integrates quality-controlled biofluid sampling, sensor fusion and metadata capture to convert raw sensor outputs into clinically valid digital biomarkers.
The High-Definition Oncology feasibility study in 30 women with metastatic cancer demonstrated high adherence to biospecimen collection (97.4% plasma, 80.7% stool) and wearable monitoring (70–95% of days captured for activity, heart rate, sleep, and oxygen saturation). This establishes a viable framework for decentralised, multimodal data collection in oncology to support individualised treatment models.
Garma et al., JCO precision oncology (paywalled) · source ↗
Wearing-off symptoms during natalizumab treatment in multiple sclerosis correlate with fatigue but not with inflammatory or neurodegenerative biomarkers, suggesting they are not markers of disease activity. Passive wearable monitoring detected subtle end-of-cycle motor declines and dynamic activity features that aligned with fatigue, indicating potential for digital biomarkers to serve as remote endpoints in decentralised neurological care.
Masanneck et al., Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (paywalled) · source ↗